Literature DB >> 6151777

Physical performance and muscle metabolism during beta-adrenergic blockade in man.

P Kaiser.   

Abstract

The major findings of the present study may be summarized as follows: Muscle strength, measured as maximal isokinetic torque and maximal dynamic muscle power, measured as the highest 5 s power output during a 30 s maximal cycle exercise test, were unaltered by beta-blockade. When maximal exercise was prolonged to 30-60 s, anaerobic endurance, measured both as average power during 30 s maximal cycle exercise and as static endurance time at 65% of maximal voluntary contraction force, was decreased by beta-blockade. On the other hand, anaerobic endurance measured as peak torque decline during 50 repeated maximal isokinetic contractions was unaffected by beta-blockade. Aerobic power, measured as maximal oxygen uptake (VO2max) during cycle exercise, was decreased by beta-blockade. In addition, aerobic endurance was decreased by beta-blockade when measured as both time to fatigue during 10 min cycling and as time for a 2000 m run. When comparing the effects of beta 1-selective and non-selective beta-blockade on work capacity, no differences were demonstrated with regard to muscle strength, muscle power, and aerobic power (VO2max). Aerobic endurance was decreased to a greater extent by non-selective than by beta 1-selective blockade, when similar reductions in heart rate and VO2 max were attained. The difference in aerobic endurance between the two types of blockers indicates that factors other than an effect on oxygen transport, are responsible for the further reduction in endurance induced by the non-selective blockade. These factors are most likely local metabolic factors. Similarly, work capacity was reduced to a greater extent by non-selective than beta 1-selective blockade when similar reduction in blood pressure were attained by both drugs in hypertensive patients. Muscle G-6-P concentration was reduced by non-selective, but not by beta 1-selective blockade, suggesting a beta 2-mediated retardation of glycolysis. The effects of beta-blockade on VO2max and work capacity shown during acute administration persisted during long-term treatment.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6151777

Source DB:  PubMed          Journal:  Acta Physiol Scand Suppl        ISSN: 0302-2994


  19 in total

Review 1.  Enhancement of athletic performance with drugs. An overview.

Authors:  J C Wagner
Journal:  Sports Med       Date:  1991-10       Impact factor: 11.136

Review 2.  Drugs and sport. Research findings and limitations.

Authors:  P M Clarkson; H S Thompson
Journal:  Sports Med       Date:  1997-12       Impact factor: 11.136

3.  Influence of angular velocity and movement frequency on development of fatigue in repeated isokinetic knee extensions.

Authors:  S E Mathiassen
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1989

4.  Ramp work tests with three different beta-blockers in normal human subjects.

Authors:  R L Hughson
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1989

5.  Biologically relevant sex differences for fitness-related parameters in active octogenarians.

Authors:  Fabian Lötscher; Tobias Löffel; Roger Steiner; Michael Vogt; Stephan Klossner; Albrecht Popp; Kurt Lippuner; Hans Hoppeler; Christoph Däpp
Journal:  Eur J Appl Physiol       Date:  2007-01-12       Impact factor: 3.078

6.  Effect of calcium channel blockade and beta-adrenoceptor blockade on short graded and single-level endurance exercises in normal men.

Authors:  L Vanhees; R Fagard; A Amery
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1988

Review 7.  Exercise performance and beta-blockade.

Authors:  P A Tesch
Journal:  Sports Med       Date:  1985 Nov-Dec       Impact factor: 11.136

8.  Blood lactate. Implications for training and sports performance.

Authors:  I Jacobs
Journal:  Sports Med       Date:  1986 Jan-Feb       Impact factor: 11.136

9.  Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin.

Authors:  P Omvik; P Lund-Johansen
Journal:  Cardiovasc Drugs Ther       Date:  1993-04       Impact factor: 3.727

10.  Modest antihypertensive effect of epanolol, a beta 1-selective receptor blocker with beta 1 agonist activity: an acute and long-term hemodynamic study at rest and during exercise and double crossover comparison with atenolol on ambulatory blood pressure.

Authors:  P Omvik; P Lund-Johansen; H Haugland
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.